Medline Inc. (MDLN) vs Moderna, Inc. (MRNA)
MDLN leads on 7 of 7 compared metrics.
A side-by-side comparison of Medline Inc. and Moderna, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 18, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
Total return — MDLN vs MRNA
growth of $100 · last 1yMDLN -11.2%MRNA +102.6%MRNA compounded faster
MDLN MRNA
MDLN vs MRNA: by the numbers
- •MDLN is the larger company ($30.23B vs $24.52B market cap).
- •MDLN is profitable (3.31% net margin) while MRNA runs a net loss (-143.55%).
Metrics side by side
Valuation
| Metric | MDLN | MRNA |
|---|---|---|
| P/E ratio | 30.10 | — |
| Forward P/E | 21.96 | — |
| P/S ratio | 1.03● | 10.97 |
| P/B ratio | 2.67● | 3.30 |
| EV / EBITDA | 14.81 | — |
| FCF yield | 5.08% | — |
Profitability
| Metric | MDLN | MRNA |
|---|---|---|
| Gross margin | 24.04%● | -13.89% |
| Operating margin | 7.04%● | -153.35% |
| Net margin | 3.31%● | -143.55% |
| ROE | 8.55%● | -43.12% |
| ROIC | 5.69%● | -29.70% |
Growth (annualized)
| Metric | MDLN | MRNA |
|---|---|---|
| Revenue CAGR (5Y) | — | -2.60% |
| FCF CAGR (5Y) | — | 126.92% |
| Total return CAGR (5Y) | — | -21.13% |
Frequently asked
- Is MDLN or MRNA more profitable?
- MDLN runs the higher net margin — MDLN at 3.31% versus MRNA at -143.55%.
Go deeper
Dig into the metrics
Medline P/E ratioModerna P/E ratioMedline dividend yieldModerna dividend yieldMedline ROEModerna ROEMedline operating marginModerna operating marginMedline revenue growthModerna revenue growthMedline free cash flowModerna free cash flow
Medline & Moderna appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 18, 2026.